Essay HJ. A hundred years of Alzheimer's disease research. Neuron. 2006;52:3–13.
Article
Google Scholar
Glenner GG, Wong CW, Quaranta V, Eanes ED. The amyloid deposits in Alzheimer's disease: their nature and pathogenesis. Appl Pathol. 1984;2:357–69.
CAS
PubMed
Google Scholar
Brion JP, Passareiro H, Nunez J, Flament-Durand J. Mise en evidence de la immunologique de la protein tau au lesions de degeneresescence neurofibrillaire de la maladie. Arch Biol (Brux). 1985;95:229–35.
Cummings J, Aisen PS, DuBois B, Frölich L, Jack Jr CR, Jones RW, et al. Drug development in Alzheimer's disease: the path to 2025. Alzheimers Res Ther. 2016. vol. 8. doi:10.1186/s13195-016-0207-9.
Hardy DJ, Selkoe J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353–6.
Article
CAS
PubMed
Google Scholar
Price JL, McKeel Jr DW, Buckles VD, Roe CM, Xiong C, Grundman M, et al. Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging. 2009;30:1026–36.
Article
PubMed
PubMed Central
Google Scholar
Vos SJ, Xiong C, Visser PJ, Jasielec MS, Hassenstab J, Grant EA, et al. Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. Lancet Neurol. 2013;12:957–65. doi:10.1016/S1474-4422(13)70194-7.
Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239–59.
Article
CAS
PubMed
Google Scholar
Gomez-Isla T, Hollister R, West H, Mui S, Growdon JH, Petersen RC, Parisi JE, Hyman BT. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol. 1997;41:17–24.
Article
CAS
PubMed
Google Scholar
De Strooper B, Karran E. The cellular phase of Alzheimer's disease. Cell. 2016;164:603–15.
Article
PubMed
Google Scholar
Raskin J, Cummings J, Hardy J, Schuh K, Dean RA. Neurobiology of Alzheimer's disease: integrated molecular, physiological, anatomical, biomarker, and cognitive dimensions. Curr Alzheimer Res. 2015;12:712–22.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ittner LM, Götz J. Amyloid-β and tau—a toxic pas de deux in Alzheimer's disease. Nat Rev Neurosci. 2011;12:65–72.
Article
CAS
PubMed
Google Scholar
Arendt T, Stieler JT, Holzer M. Tau and tauopathies. Brain Res Bull. 2016;126:238–92.
Article
CAS
PubMed
Google Scholar
Crary JF, Trojanowski JQ, Schneider JA, et al. Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol. 2014;128:755–66.
Article
CAS
PubMed
PubMed Central
Google Scholar
Jellinger KA, Alafuzoff I, Attems J, Beach TG, Cairns NJ, Crary JF, et al. PART, a distinct tauopathy, different from classical sporadic Alzheimer disease. Acta Neuropathol. 2015;129:757–62.
Article
PubMed
PubMed Central
Google Scholar
Sperling RA, Aisen P, Beckett L, Bennett DA, Craft S, Fagan AM, et al. Towards defining the preclinical stage of Alzheimer’s disease: recommendations from the National Institute on Aging and the Alzheimer’s Association workgroup. Alzheimers Dement. 2011;7:280–92.
Article
PubMed
PubMed Central
Google Scholar
Mormino EC, Betensky RA, Hedden T, Schultz AP, Ward A, Huijbers W, et al. Amyloid and APOE ε4 interact to influence short-term decline in preclinical Alzheimer disease. Neurology. 2014;82:1760–7. doi:10.1212/WNL.0000000000000431.
Stern Y. Cognitive reserve in ageing and Alzheimer's disease. Lancet Neurol. 2012;11:1006–12.
Article
PubMed
PubMed Central
Google Scholar
Ngandu T, Lehtisalo J, Solomon A, Levälahti E, Ahtiluoto S, Prof Antikainen R, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015;385:2255–63. doi:10.1016/S0140-6736(15)60461-5.
Rusanen M, Kivipelto M, Quesenberry Jr CP, Zhou J, Whitmer RA. Heavy smoking in midlife and long-term risk of Alzheimer disease and vascular dementia. Arch Intern Med. 2011;171:333–9.
Article
PubMed
Google Scholar
Solomon A, Mangialasche F, Richard E, Andrieu S, Bennett DA, Breteler M, et al. Advances in the prevention of Alzheimer's disease and dementia. J Intern Med. 2014;275:229–50. doi:10.1111/joim.1217.
PREVENT Dementia. http://preventdementia.co.uk/. Accessed 10 March 2017.
Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo J, Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo J, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol. 2014;13:614–29. Erratum in: Lancet Neurol. 2014;13:757.
Article
PubMed
Google Scholar
Jack Jr CR, Wiste HJ, Vemuri P, Weigand SD, Senjem ML, Zeng G, et al. Alzheimer's Disease Neuroimaging Initiative. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain. 2010;133:3336–48.
Jack Jr CR, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12:207–16.
Article
CAS
PubMed
PubMed Central
Google Scholar
Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, et al. Dominantly Inherited Alzheimer Network. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012;367:795–804.
Article
CAS
PubMed
PubMed Central
Google Scholar
Benzinger TL, Blazey T, Jack Jr CR, Koeppe RA, Su Y, Xiong C, et al. Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. Proc Natl Acad Sci U S A. 2013;110:E4502–9. doi:10.1073/pnas.
Fleisher AS, Chen K, Quiroz YT, Jakimovich LJ, Gutierrez Gomez M, Langois CM, et al. Associations between biomarkers and age in the presenilin 1 E280A autosomal dominant Alzheimer disease kindred: a cross-sectional study. JAMA Neurol. 2015;72:316–24. doi:10.1001/jamaneurol.2014.3314.
van Rossum IA, Visser PJ, Knol DL, van der Flier WM, Teunissen CE, Barkhof F, et al. Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease. J Alzheimers Dis. 2012;29:319–27.
PubMed
Google Scholar
Ossenkoppele R, Schonhaut DR, Schöll M, Lockhart SN, Ayakta N, Baker SL, et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. Brain. 2016;139:1551–67.
Article
PubMed
PubMed Central
Google Scholar
Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. 2013;12:357–67. doi:10.1016/S1474-4422(13)70044-9.
Ossenkoppele R, Cohn-Sheehy BI, La Joie R, Vogel JW, Möller C, Lehmann M, et al. Atrophy patterns in early clinical stages across distinct phenotypes of Alzheimer's disease. Hum Brain Mapp. 2015;36:4421–37.
Article
PubMed
PubMed Central
Google Scholar
Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FR, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA. 2015;313:1924–38. doi:10.1001/jama.2015.4668.
Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261:921–3.
Article
CAS
PubMed
Google Scholar
Chartier-Harlin MC, Parfitt M, Legrain S, Pérez-Tur J, Brousseau T, Evans A, et al. Apolipoprotein E, epsilon 4 allele as a major risk factor for sporadic early and late-onset forms of Alzheimer's disease: analysis of the 19q13.2 chromosomal region. Hum Mol Genet. 1994;3:569–74.
Article
CAS
PubMed
Google Scholar
Petersen RC, Wiste HJ, Weigand SD, Rocca WA, Roberts RO, Mielke MM, et al. Association of elevated amyloid levels with cognition and biomarkers in cognitively normal people from the community. JAMA Neurol. 2016;73:85–92. Erratum in: JAMA Neurol. 2016;73:481.
Article
PubMed
PubMed Central
Google Scholar
Johnson DK, Storandt M, Morris JC, Galvin JE. Longitudinal study of the transition from healthy aging to Alzheimer disease. Arch Neurol. 2009;66:1254–9.
Article
PubMed
PubMed Central
Google Scholar
Donohue MC, Sperling RA, Salmon DP, Rentz DM, Raman R, Thomas RG, et al. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol. 2014;71:961–70.
Article
PubMed
PubMed Central
Google Scholar
Jessen F. Subjective and objective cognitive decline at the pre-dementia stage of Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci. 2014;264:S3–7.
Article
PubMed
Google Scholar
Liu-Seifert H, Siemers E, Price K, Han B, Selzler KJ, Henley D, et al. Cognitive impairment precedes and predicts functional impairment in mild Alzheimer’s disease. J Alzheimers Dis. 2015;47:205–14.
Article
CAS
PubMed
PubMed Central
Google Scholar
Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6:734–46.
Article
PubMed
Google Scholar
Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:270–9.
Article
PubMed
PubMed Central
Google Scholar
McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawash CH, et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging and the Alzheimer’s Association workgroup. Synergistic effect of β-amyloid and neurodegeneration on cognitive decline in clinically normal individuals. JAMA Neurol. 2014;71:1379–85.
Article
Google Scholar
Wagner M, Wolf S, Reischies FM, Daerr M, Wolfsgruber S, Jessen F, et al. Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease. Neurology. 2012;78:379–86.
Article
CAS
PubMed
Google Scholar
Jekel K, Damian M, Wattmo C, Hausner L, Bullock R, Connelly PJ, et al. Mild cognitive impairment and deficits in instrumental activities of daily living: a systematic review. Alzheimers Res Ther. 2015;7:17.
Article
PubMed
PubMed Central
Google Scholar
Jack Jr CR, Bennett DA, Blennow K, Carrillo MC, Feldman HH, Frisoni GB, et al. A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016;87:539–47.
Article
CAS
PubMed
PubMed Central
Google Scholar
Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, Bakardjian H, et al. Proceedings of the Meeting of the International Working Group (IWG) and the American Alzheimer's Association on “The Preclinical State of AD”; July 23, 2015; Washington DC, USA. Alzheimers Dement. 2016;12:292–323.
Article
PubMed
Google Scholar
Arnerić SP, Batrla-Utermann R, Beckett L, Bittner T, Blennow K, Carter L, et al. Cerebrospinal fluid biomarkers for Alzheimer's disease: a view of the regulatory science qualification landscape from the Coalition Against Major Diseases CSF Biomarker Team. J Alzheimers Dis. 2017;55:19–35.
Article
PubMed
Google Scholar
Chételat G, La Joie R, Villain N, Perrotin A, de La Sayette V, Eustache F, Vandenberghe R. Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease. Neuroimage Clin. 2013;2:356–65. doi:10.1016/j.nicl.2013.02.006.
Johnson KA, Schultz A, Betensky RA, Becker JA, Sepulcre J, Rentz D, et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol. 2016;79:110–9.
Article
PubMed
Google Scholar
Siemers E, Sundell K, Carlson C, Case M, Sethuraman G, Liu-Seifert H, et al. Phase 3 solanezumab trials: secondary outcomes in mild Alzheimer’s disease patients. Alzheimers Dement. 2016;12:110–20.
Article
PubMed
Google Scholar
Petersen RC, Aisen P, Boeve BF, Geda YE, Ivnik RJ, Knopman DS, et al. Mild cognitive impairment due to Alzheimer disease in the community. Ann Neurol. 2013;74:199–208.
PubMed
PubMed Central
Google Scholar
Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer’s disease. The Alzheimer’s disease Cooperative Study. Alzheimer’s Disease and Associated Disorders. 1997;11:S33–9.
Article
Google Scholar
Hamel R, Köhler S, Sistermans N, Koene T, Pijnenburg Y, van der Flier W, et al. The trajectory of cognitive decline in the pre-dementia phase in memory clinic visitors: findings from the 4C-MCI study. Psychol Med. 2015;45:1509–19.
Article
CAS
PubMed
Google Scholar
Walsh SP. Raman R, Jones KB, Aisen PS, Alzheimer's Disease Cooperative Study Group. ADCS Prevention Instrument Project: the Mail-In Cognitive Function Screening Instrument (MCFSI). Alzheimer Dis Assoc Disord. 2006;20:S170–8.
Article
PubMed
Google Scholar
Marson DC, Sawrie SM, Snyder S, McInturff B, Stalvey T, Boothe A, et al. Assessing financial capacity in patients with Alzheimer disease: a conceptual model and prototype instrument. Arch Neurol. 2000;57:877–84.
Article
CAS
PubMed
Google Scholar
Buschke H, Kuslansky G, Katz M, Stewart WF, Sliwinski MJ, Eckholdt HM, Lipton RB Screening for dementia with the Memory Impairment Screen H. Neurology. 1999;52:231–8. doi:10.1212/WNL.52.2.231.
Grober E, Buschke H. Genuine memory deficits in dementia. Dev Neuropsychol. 1987;3:13–36.
Article
Google Scholar
Galvin JE, Roe CM, Powlishta KK, Coats MA, Muich SJ, Grant E, Miller JP, Storandt M, Morris JC. The AD8: a brief informant interview to detect dementia. Neurology. 2005;65:559–64.
Article
CAS
PubMed
Google Scholar
Wang J, Logovinsky V, Hendrix S, Stanworth S, Perdoma C, Xu L, et al. ADCOMS: a composite clinical outcome for prodromal Alzheimer’s disease trials. J Neurol Neurosurg Psychiatry. 2016;87:993–9. doi:10.1136/jnnp-2015-312383.
Brodaty H, Pond D, Kemp NM, Luscombe G, Harding L, Berman K, Huppert FA. The GPCOG: a new screening test for dementia designed for general practice. J Am Geriatr Soc. 2002;50:530–4.
Article
PubMed
Google Scholar
Borson S, Scanlan J, Brush M, Vitaliano P, Dokmak A. The mini-cog: a cognitive “vital signs” measure for dementia screening in multi-lingual elderly. Int J Geriatr Psychiatry. 2000;15:1021–7.
Article
CAS
PubMed
Google Scholar
Randolph C, Tierney MC, Mohr E, Chase TN. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J Clin Exp Neuropsych. 1988;20:310–9.
Article
Google Scholar
Dubois B, Touchon J, Portet F, Ousset PJ, Vellas B, Michel B. The “5-words”: a simple and sensitive test for the diagnosis of Alzheimer’s disease. Presse Med. 2002;31:1696–9.
CAS
PubMed
Google Scholar
Mormont E, Jamart J. Robaye L Validity of the five-word test for the evaluation of verbal episodic memory and dementia in a memory clinic setting. J Geriatr Psychiatry Neurol. 2012;25:78–84.
Article
PubMed
Google Scholar
Elwood RW. The California Verbal Learning Test: psychometric characteristics and clinical application. Neuropsychol Rev. 1995;5:173–201.
Article
CAS
PubMed
Google Scholar
Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53:695–9.
Article
PubMed
Google Scholar
Noone P. Addenbrooke’s Cognitive Examination-III. Occup Med (Lond). 2015;65:418–20. doi:10.1093/occmed/kqv041.
Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–98.
Article
CAS
PubMed
Google Scholar
Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984;41:1356–64.
Google Scholar
Berg L. Clinical Dementia Rating (CDR). Psychopharm Bull. 1988;24:637–9.
CAS
Google Scholar
Saxton J, Swihart AA. Neuropsychological assessment of the severely impaired elderly patient. Clin Geriatr Med. 1989;5:531–43.
CAS
PubMed
Google Scholar